AstraZeneca PLC Add to portfolio

LON100:AZN, Sep 30, 02:55 UTC

Latest LON100:AZN News

Filter your feed

Apply Filter

Monday, September 28


News

Astrazeneca (AZN) Stock Sinks As Market Gains: What You Should Know

AZN AZN

Investors will be hoping for strength from AZN as it approaches its next earnings release. Meanwhile, our latest consensus estimate is calling for revenue of $6.66 billion, up 3.92% from the prior-year quarter. For the full year, our Zacks Consensus Estimates are projecting earnings of $2.03 per share and revenue of $26.26 billion, which would represent changes of +16% and +7.69%, respectively, from the prior year. Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Its industry sports an average Forward P/E of 14.57, so we one might conclude that AZN is trading at a premium comparatively.

Read Full Details

Topics:
  • Business
  • Financial

Friday, September 25


News

Canada has signed deal for AstraZeneca vaccine candidate - PM

AZN AZN

Canada has signed deal for AstraZeneca vaccine candidate - PM. {{monthName}} {{day}}, {{year}}, {{hour12}}:{{minuteTwoDigit}} {{dayPeriod}}. OTTAWA, Sept 25 (Reuters) - Canada has signed a deal with Cambridge-based AstraZeneca to buy up to 20 million doses of its COVID-19 vaccine candidate, Prime Minister Justin Trudeau told reporters on Friday. The medication is among the leading candidates in the global race for a vaccine, now in late-stage trials in Britain, South Africa and elsewhere. (Reporting by David Ljunggren) View more on Yahoo Finance.

Read Full Details

Topics:
  • Health
  • Technology
  • Business
  • Financial
News

AstraZeneca gets partial immunity in low-cost EU vaccine deal

AZN AZN

EU states to pay part of legal bill in case of problems. AstraZeneca got partial waiver for low vaccine price. Filling and packaging tests for the large-scale production and supply of the University of Oxford's COVID-19 vaccine candidate, AZD1222, taking place at a site southeast of Rome, Italy, on September 11, 2020. European governments will pay claims above an agreed limit against AstraZeneca over side-effects from its potential COVID-19 vaccine, under different terms to a deal struck with Sanofi, an EU official toldReuters. The deals reflect different strategies by two of the world's top drugmakers for protecting themselves as a debate rages about liabilities for vaccines aimed at ending the pandemic. AstraZeneca has secured the European Union's backing in a confidential agreement which reflects the lower price sought by the British drugmaker, the official said.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
News

Exclusive: AstraZeneca gets partial immunity in low-cost EU vaccine deal

AZN AZN

BRUSSELS (Reuters) - European governments will pay claims above an agreed limit against AstraZeneca over side-effects from its potential COVID-19 vaccine, under different terms to a deal struck with Sanofi, an EU official told Reuters. The deals reflect different strategies by two of the world's top drugmakers for protecting themselves as a debate rages about liabilities for vaccines aimed at ending the pandemic. AstraZeneca <AZN.L> has secured the European Union's backing in a confidential agreement which reflects the lower price sought by the British drugmaker, the official said. The deal with AstraZeneca, which shifts some of the risks involved in the roll-out of a vaccine to taxpayers, was struck in August and its liability clauses have not previously been reported. Under the AstraZeneca deal, EU countries have agreed to pay 2.5 euros ($2.92) per dose, while Sanofi has negotiated a price at around 10 euros, the official said. As part of the supply deals, the only two sealed so far by Brussels, the EU has also made a non-refundable downpayment of 336 million euros to AstraZeneca to secure 400 million doses, proportionately lower than the 324 million euros it paid to Sanofi to secure 300 million doses.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
  • Politics
  • US
News

Exclusive: AstraZeneca gets partial immunity in low-cost EU vaccine deal

AZN AZN

BRUSSELS (Reuters) - European governments will pay claims above an agreed limit against AstraZeneca over side-effects from its potential COVID-19 vaccine, under different terms to a deal struck with Sanofi, an EU official told Reuters. The deals reflect different strategies by two of the world's top drugmakers for protecting themselves as a debate rages about liabilities for vaccines aimed at ending the pandemic. AstraZeneca <AZN.L> has secured the European Union's backing in a confidential agreement which reflects the lower price sought by the British drugmaker, the official said. The deal with AstraZeneca, which shifts some of the risks involved in the roll-out of a vaccine to taxpayers, was struck in August and its liability clauses have not previously been reported. Under the AstraZeneca deal, EU countries have agreed to pay 2.5 euros ($2.92) per dose, while Sanofi has negotiated a price at around 10 euros, the official said. As part of the supply deals, the only two sealed so far by Brussels, the EU has also made a non-refundable downpayment of 336 million euros to AstraZeneca to secure 400 million doses, proportionately lower than the 324 million euros it paid to Sanofi to secure 300 million doses.

Read Full Details

Topics:
  • Business
  • Politics
  • Financial
  • US
  • Health

Thursday, September 24


News

UK shares drop as job support scaled back; AstraZeneca weighs

AZN AZN

U.S. UK shares drop as job support scaled back; AstraZeneca weighs. (Reuters) - London shares dropped on Thursday, hitting session lows after Britain scaled-back job support for workers hit by the resurgent coronavirus pandemic, while AstraZeneca slid as U.S. trials for its COVID-19 vaccine remained on hold. After two days of gains driven by new restrictions to curb a resurgence in COVID-19 cases being less severe than expected, the blue-chip FTSE 100 index .FTSE fell 1.3%, while the mid-caps index .FTMC closed down 1.1%. British finance minister Rishi Sunak unveiled plans to extend loan repayments for businesses and delay ending a tax cut for the hospitality sector. But under a new programme to replace the job retention scheme, which ends next month, government support will only be available to workers whose employers keep them on at least a third of their normal hours, Sunak said. While the measures will go some way to cushioning the blow to economic recovery and limiting the long-term hit to unemployment, it won't eliminate the hit entirely, said Ruth Gregory, senior UK economist with Capital Economics, adding this could see GDP stagnate in the last three months of the year.

Read Full Details

Topics:
  • Business
  • Financial
News

AstraZeneca still waiting for FDA go-ahead to resume U.S. trial

AZN AZN

FRANKFURT (Reuters) - AstraZeneca <AZN.L> is still waiting for the U.S. drug regulator to approve the restart of the clinical trial of its potential COVID-19 vaccine in the United States almost three weeks after it was paused due to safety concerns. The U.S. trial of AstraZeneca's COVID-19 vaccine candidate, initially developed by the University of Oxford, remains on hold while regulators investigate an illness in one of the participants, even after a British study and other programmes outside of the United States have resumed. "We are the sponsor of the U.S. study. We then provided all this information to the FDA (U.S. Food and Drug Administration) and we are waiting to hear their decision," Soriot told a virtual World Economic Forum discussion. A document posted online by Oxford university last week stated the illness in a British participant that triggered the pause on Sept. 6 may not have been associated with the vaccine. Asked why the company had not disclosed details about the nature of the illness, Soriot said clinical trial regulators and independent supervisors were guarding participants' privacy.

Read Full Details

Topics:
  • Health
  • Technology
  • Business
  • Financial

Wednesday, September 23


News

Scientists Question Why AstraZeneca COVID-19 Vaccine Trial Remains On Hold In US

AZN AZN

Scientists Question Why AstraZeneca COVID-19 Vaccine Trial Remains On Hold In US. Scientists are questioning why AstraZeneca Plc’s (NYSE: AZN) COVID-19 vaccine clinical trials remain paused in the United States even as other countries move forward. What Happened: The British pharma company’s trials were temporarily grounded across the globe after one of the volunteers faced complications in the U.K. However, these trials have begun in most countries, except the U.S. — where has been on hold for over two weeks. Johns Hopkins Center immunologist Gigi Gronvall concurred with Jha, saying the U.S. regulator and AstraZeneca need to be more open about why the clinical trial hasn't resumed. The trials were halted after a participant developed neurological symptoms, but Oxford University, which co-developed the vaccine candidate alongside AstraZeneca, said the unexplained adverse reactions in trial volunteers were likely unrelated to the vaccine.

Read Full Details

Topics:
  • Business
  • Health
  • Technology
  • Financial

Tuesday, September 22


News

AstraZeneca's Lynparza Gets CHMP Nod for Two New Indications

AZN AZN

{{monthName}} {{day}}, {{year}}, {{hour12}}:{{minuteTwoDigit}} {{dayPeriod}}. AstraZeneca AZN announced that the European Medicines Agency’s (“EMA”) Committee for Medicinal Products for Human Use (“CHMP”) has rendered a positive opinion recommending the approval of its PARP inhibitor, Lynparza (olaparib) for two label expansions in Europe. The CHMP also recommended approving the drug for metastatic castration-resistant prostate cancer (mCRPC) with germline and/or somatic BRCA mutations in patients whose disease has progressed following prior treatment with new hormonal agent treatments like J&J’s JNJ Zytiga and Pfizer PFE/Astellas’ Xtandi. Shares of AstraZeneca have gained 12.1% so far this year compared with the industry’s increase of 1.8%. Moreover, label expansion of the drug also helps it to maintain its leadership compared to two other approved PARP inhibitors — Glaxo’s Zejula and Clovis Oncology’s Rubraca. AstraZeneca PLC Price. AstraZeneca PLC price | AstraZeneca PLC Quote.

Read Full Details

Topics:
  • Business
  • Health
News

Chart Of The Day: AstraZeneca's Fundamentals, Technicals Continue To Diverge

AZN AZN

The strongest and fastest equity market rally in decades, which occurred from the March 2020 lows till mid-September of this year, was fueled by two complementary fundamental themes: the Federal Reserve’s "whatever it takes, as long as it takes" support of the US's COVID-19 ravaged economy and the ongoing promise of a vaccine that would alleviate the global pandemic. As such, shares of any big pharmaceuticals company or smaller biotech whose clinical trials showed any promise at all regarding the advancement of a coronavirus vaccine was rapidly rewarded by investors starved for both hope and an end to the heavy pressure of the pandemic as it weighed global markets. In early September, the drugmaker, working with researches at Oxford University, voluntarily paused its clinical trial, after one of the trial participants developed a serious side effect, thought to be from the experimental vaccine. But when a second participant developed unexplained neurological symptoms, the US's Food and Drug Administration (FDA) enforced a pause while it conducts a safety review. Though an independent review noted that the illnesses were likely not related to the vaccine, and trials in the UK, Brazil and South Africa have resumed, the FDA investigation is ongoing, thus US trials remain paused. Negative headlines are never good for a stock, so it makes sense that shares of AstraZeneca have slipped. But why did the stock plunge a full 4%, after peaking on July 20 when the company's vaccine showed promise in trials?

Read Full Details

Topics:
  • Business
  • Health
  • Financial